Victory Capital Management Inc Inhibrx, Inc. Transaction History

Victory Capital Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$20.18 - $33.33 $671,994 - $1.11 Million	-33,300 Reduced 43.33%	43,560 $1.07 Million
Q3 2022 Nov 02, 2022	SELL	$11.58 - $24.73 $141,276 - $301,706	-12,200 Reduced 13.7%	76,860 $1.38 Million
Q2 2022 Aug 01, 2022	SELL	$8.52 - $25.26 $92,791 - $275,106	-10,891 Reduced 10.9%	89,060 $1.01 Million
Q1 2022 May 04, 2022	BUY	$19.89 - $43.18 $338,090 - $733,973	16,998 Added 20.49%	99,951 $2.16 Million
Q4 2021 Feb 07, 2022	SELL	$26.75 - $46.02 $1.68 Million - $2.88 Million	-62,687 Reduced 43.04%	82,953 $3.62 Million
Q3 2021 Nov 02, 2021	BUY	$25.18 - $37.81 $1.92 Million - $2.89 Million	76,310 Added 110.07%	145,640 $4.85 Million
Q2 2021 Aug 03, 2021	SELL	$14.69 - $27.52 $64,929 - $121,638	-4,420 Reduced 5.99%	69,330 $1.91 Million
Q1 2021 May 04, 2021	SELL	$16.27 - $41.26 $495,421 - $1.26 Million	-30,450 Reduced 29.22%	73,750 $1.48 Million
Q4 2020 Feb 01, 2021	SELL	$15.96 - $50.0 $259,030 - $811,500	-16,230 Reduced 13.48%	104,200 $3.44 Million
Q3 2020 Nov 09, 2020	BUY	$16.77 - $20.65 $2.02 Million - $2.49 Million	120,430 New	120,430 $2.17 Million

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $617M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.